Piper Sandler Companies has announced the addition of Kelsey Goodwin as a director and senior research analyst to their biotechnology equity research team. Goodwin, who will be based in the Boston office, will have coverage responsibilities in oncology. She joins the firm after seven years at Guggenheim, where she focused on oncology, and previously worked in pharmaceutical strategy consulting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Piper Sandler Companies published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625516743) on June 25, 2025, and is solely responsible for the information contained therein.